-
Why is it difficult for GlaxoSmithKline's 10 billion dollar single product to sell in the shingles vaccine market in China?
Zhang Li (pseudonym) is not yet 40 years old this year, but he was approached by shingles a year ago. This is a disease that is compared to "immortal cancer" and has a high pain index, which is more ... -
MSD World's Second Largest Animal Vaccine Research and Development Center Completed in Ningbo
According to MSD China, the opening ceremony of the MSD Animal Health China R&D and Process Technology Center was held in Ningbo on November 13th. The center will become the world's second largest an ... -
Pfizer China Dismiss Star Pneumonia Vaccine Product Team and Change to Shanghai Pharmaceutical Agency for Promotion and Sales
On November 24th, a netizen on social media platform Xiaohongshu reported that the Pfizer China 13 valent pneumococcal polysaccharide conjugate vaccine (PCV13 vaccine, product name: Pei'er 13, Preven ... -
Behind the layoffs of Pfizer's vaccine team: The issuance of 13 batches of Star Vaccine Pei'er has plummeted sharply, and it has also been surrounded by domestic production
Recently, Pfizer's vaccine team in China reported layoffs. Its 13 valent pneumococcal polysaccharide conjugate vaccine (PCV13 vaccine, trade name: Pei'er 13, Prevenar 13), which is currently being so ... -
Top 20 US Stock Deals: Pfizer Encounters Double Killing Lawsuit between Diet Drugs and COVID-19 Vaccine
[The top 20 US stock turnover: Pfizer suffered a double battle between weight-loss drugs and COVID-19 vaccine litigation] The 12th Pfizer Pharmaceutical closed down 5.12%, the largest one-day decline ... -
Merck's Q4 performance exceeded expectations! Strong sales of heavyweight anti-cancer drugs and HPV vaccines
US pharmaceutical giant Merck (also known as Merck outside the US and Canada) released its quarterly report on Thursday, with fourth quarter revenue and adjusted profits exceeding expectations due to ... -
Li Zhengqing, Senior Vice President Global and President of Research and Development in China at Merck: Nine valent HPV vaccine adds a second dose vaccination program for women aged 9-14, and Merck "increases efforts" to eliminate cervical cancer
On January 9, 2024, MSD announced that its second dose vaccination program for the nine valent human papillomavirus (HPV) vaccine targeting women aged 9-14 has been approved by the National Medical P ... -
Merck's imported hepatitis A vaccine has been in widespread shortage in China for more than half a year and has not been approved for issuance
Merck's imported inactivated hepatitis A vaccine is experiencing widespread shortages in many parts of China. Interface News reporters have observed in the past three months that there is a shortage ... -
Merck's response to shortage of hepatitis A vaccines: new batches have entered circulation and supply this month
On February 29th, regarding the large-scale shortage of imported hepatitis A vaccines in China, MSD China exclusively responded to Interface News that a new batch of MSD hepatitis A vaccines had been ... -
GlaxoSmithKline: The protection rate of Shingrix vaccine against herpes zoster still reaches 82% after 11 years of injection
GlaxoSmithKline recently released long-term protection data for the herpes zoster vaccine. Research has shown that for people over 50 years old, the cumulative protection rate from the 6th to 11th ye ...